1 published article · Updated continuously
6 trials tracked for Intra-abdominal infection: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 23 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Tigecycline has demonstrated significant clinical response rates in patients with intra-abdominal infections. In a Phase 4 study, the clinical response at the Test-of-Cure (TOC) assessment was reported as 89.9% in the Clinically Evaluable population 1, 82.8% in the Modified Intent-to-Treat population 1, and 88.0% in the Microbiologically Evaluable population 1. A separate Phase 4 trial confirmed high clinical response rates for tigecycline among Microbiologically Evaluable patients (97 vs. 86, p=0.001) 3.
Alternative antibiotic regimens also show established outcomes for intra-abdominal infections. Ceftolozane and tazobactam (MK-7625A) demonstrated a 92.0% clinical response rate at the Test-of-Cure visit, with no participants discontinuing the study drug due to adverse events 4. In comparison, Zavicefta (ceftazidime-avibactam) showed a 59.3% clinical cure rate in the mMITT analysis and a 78.6% clinical cure rate in the ME analysis at the Test-of-Cure visit 2.
Regarding resource utilization, tigecycline was associated with no statistically significant difference in the number of days of inpatient healthcare resource utilization on or before the Test-of-Cure assessment (p=0.750) 3.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
